Table 2.
Treatment administration.
| Pyrotinib treatment | No. (%) (n = 35) |
|---|---|
| Regimens | |
| Combined chemotherapy regimen | |
| Capecitabine | 18 (51.4) |
| Vinorelbine | 6 (17.1) |
| Taxane | 9 (25.7) |
| Eribulin | 1 (2.9) |
| Other | 1 (2.9) |
| Combined with trastuzumab | |
| Yes | 21 (60.0) |
| No | 14 (40.0) |
| Combined with local therapy for brain metastasis | |
| Gamma Knife | 8 (22.9) |
| Whole brain radiotherapy | 5 (14.3) |
| Unknown | 2 (5.7) |
| None | 20 (57.1) |
| Lines of systematic therapy of pyrotinib | |
| 1 | 2 (5.7) |
| 2 | 11 (31.4) |
| ≥3 | 22 (62.9) |
| Across lines therapy of pyrotinib | |
| Yes | 17 (48.6) |
| No | 18 (51.4) |
| Duration of pyrotinib (months) | |
| <3 | 3 (8.6) |
| ≥3 to <12 | 13 (37.1) |
| ≥12 | 19 (54.3) |
| Dosage Starting dosage (mg/day) | |
| 400 | 20 (57.1) |
| 320 | 7 (20.0) |
| 240 | 6 (17.1) |
| 160 | 2 (5.7) |
| Dosage reduction (mg/day) | |
| 400→320 | 4 (11.4) |
| 400→240 | 1 (2.9) |
| 320→240 | 1 ((2.9) |
| 240→160 | 3 (8.6) |
| Total | 35 (100.0) |
Values are presented as number (%). Across lines of therapy of pyrotinib: patients who received multiple lines of pyrotinib.